Rapid Biosensor Systems to launch breathalyzer test
This article was originally published in The Gray Sheet
Executive Summary
Rapid Biosensor Systems is planning an initial March debut of its TB Breathalyzer, a light-weight, portable, non-invasive screening device for early-stage tuberculosis. While initial launches will be in India and South Africa, the Cambridge, England, company says it will simultaneously begin the approval processes with FDA and Great Britain's Medicines and Healthcare Products Regulatory Agency. The breathalyzer delivers a positive or negative result with 95% accuracy within minutes, as opposed to the most prevalent test for TB in use, the Mantoux TB test, which involves a 72-hour wait time, according to the company
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.